Pfizer
Banner

What could biologics and biosimilars

mean for patients?

A meaningful impact on patient care

Biologic medicines, including biosimilars, come in different forms, such as monoclonal antibodies and growth factors. Their capacity to precisely target signaling pathways and cells is revolutionizing the battle against challenging disease areas.

biologics AND THEIR BIOSIMILARS have been used successfully to
treat many different life-threatening and chronic diseases

image of Kidney
kidney diseases images

kidney cancer

a person testing sugar level using blood from index finger
Diabetes image

diabetes

stream of blood cells
Hemotologic diseases image

blood cancers

Image of Lungs
Respiratory diseases image

lung cancer

Breast cancer cells
Cancers image

breast cancer

image of inside of intestines
Gastrointestinal diseases image

gastrointestinal
diseases

a person holding hands of another person
inflammatory diseases image

inflammatory
diseases

stream of cells with a lump of cells in it
Cardiovascular diseases image

cardiovascular
diseases

cell representing immunologic disease
Immunologic disease image

immunologic
diseases

cells representing lysosomal disease
Lysosomal disease image

lysosomal
diseases


EXPANDING OPTIONS

As potential alternatives to reference biologics, biosimilars may potentially expand treatment options to meet the growing demand for biologic therapies.

Biosimilars may improve access to biologics

Biosimilars have the potential to make a positive impact on patients by offering additional treatment choices to patients, physicians, and payers at a lower cost to the healthcare system. These savings to the healthcare system may enable more patients to have access to biologics, which could result in improved health outcomes for patients.

Biosimilars may help reduce the out-of-pocket costs of biologic medicines

One of the main reasons biosimilars were introduced in the United States was to potentially lower healthcare costs. As such, it is expected that healthcare providers, such as clinics or hospitals, will be able to acquire biosimilars at a lower wholesale cost than their reference products. Because of this, biosimilars may have the potential to lower out-of-pocket costs for patients with costsharing requirements, such as coinsurance and co-payments.

For example, patients who may pay less in the form of coinsurance include:

  • Patients covered by Medicare Part B who don’t have supplemental insurance and typically pay 20% of the Medicare-approved amount for most outpatient therapies
  • Patients with private insurance who are required to pay coinsurance for specialty drugs, including biologics

Biosimilars may also provide cost savings to the healthcare system overall.

Check with your healthcare provider or insurance company about your coverage details.

Close
Close

You are now leaving Pfizer

Links to sites outside of Pfizer are provided as a resource to the viewer. Pfizer accepts no responsibility for the content of linked sites.

Close

The information provided in this website is intended only for healthcare professionals in the United States. The products discussed may have different product labeling in different countries.

Close